2026-06-29T08:14:09Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1071222025-03-18T14:16:10Zcom_20.500.14352_14col_20.500.14352_15

Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide Huntley, Dixie Giménez, Estela Pascual, María Jesús Remigia, María José Amat, Paula Vázquez, Lourdes Hernández Martín, Marta María Hernández Boluda, Juan Carlos Gago, Beatriz Piñana, José Luis García, Magdalena Martínez, Ariadna Mateo, Eva Gozalbo Rovira, Roberto Albert, Eliseo Solano, Carlos Navarro, David 61 CMV CMV DNAemia haploidentical hematopoietic stem cell transplantation CMV CD8+ T cells CMV CD4+ T cells Ciencias Biomédicas 32 Ciencias Médicas Abstract Cytomegalovirus (CMV) DNAemia and CMV disease have been reported as more frequent in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HSCT) than in those receiving HLA-matched allografts. This could be due to impaired CMV-specific T-cell reconstitution. Here, we conducted a multicenter observationalstudy to assess CMV pp65 and IE-1-specific T cells kinetics in patients undergoing unmanipulated Haplo-HSCT with posttransplant cyclophosphamide (PT/Cy-haplo) and compared it with patients allografted with HLA-matched donors. PlasmaCMV DNA load was monitored by real-time PCR and enumeration of CMV-specific IFN-γ-producing CD8+ and CD4+T cells was performed by flow cytometry for intracellular cytokine staining at days +30, +60, +90, and +180 aftertransplantation. CMV DNAemia developed in 62 patients, occurring with comparable frequency in PT/Cy-haplo and MRD/ MUD recipients (P =0.14). There were no significant differences across groups in the number of patients either displayingdetectable CMV-specific CD8+ and CD4+ T-cell responses or acquiring CMV-specific T-cell levels conferring protectionagainst subsequent infection. CMV-specific T-cell counts were comparable between groups at most time points examined,irrespective of whether CMV DNAemia occurred or not prior to monitoring. Collectively the data suggest that PT/Cy-haplorecipients may reconstitute CMV-specific T-cell immunity to the same extent as patients undergoing HLA-matched allo-HSCT. Depto. de Enfermería Fac. de Enfermería, Fisioterapia y Podología TRUE pub Pagado por el autor 2024-07-24T11:50:22Z 2024-07-24T11:50:22Z 2020-03-23 journal article AM https://hdl.handle.net/20.500.14352/107122 0268-3369 1476-5365 10.1038/s41409-020-0865-x eng grant 15/0090 from FIS (Fondo de Investigaciones Sanitarias), Ministerio de Sanidad y Consumo, Spain Huntley, D., Giménez, E., Pascual, M.J. et al. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplant 55, 1347–1356 (2020). https://doi.org/10.1038/s41409-020-0865-x Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ open access application/pdf Springer Nature